Founded
1987
39 years
Employees
1001-5000
Annual Revenue
Not Disclosed
(2026)
Products
2
ArisGlobal provides cloud-based software solutions for the healthcare industry focused on drug development. Founded in 1987, the company delivers the LifeSphere platform serving medical affairs, clinical development, pharmacological, and drug safety functions across the pharmaceutical product lifecycle.
The company was acquired by Nordic Capital on June 17, 2019 for $700 million. Additional investors include Athyrium Capital Management and Abbhi Capital. ArisGlobal serves major pharmaceutical companies including AstraZeneca, Teva, Roche, and a global sixth-largest pharmaceutical company.
ArisGlobal's product portfolio spans regulatory information management (RIM), safety/pharmacovigilance, and NavaX AI capabilities. The company recently launched a RIM solution purpose-built for investigational-stage companies, expanding its market coverage across drug development stages.
ArisGlobal is pharma-specialised, serving the healthcare industry with a focus on drug development. Named customers include AstraZeneca, Teva, Roche, and a global sixth-largest pharmaceutical company.
The company serves pharmaceutical companies across the drug development lifecycle, from investigational stage through marketed products. A RIM solution launched for investigational-stage companies extends coverage to earlier development stages.
Platform focus areas include medical affairs, clinical development, pharmacological, and drug safety, all pharma-specific functions. The LifeSphere platform is designed for regulatory, safety/pharmacovigilance, and medical affairs needs in life sciences.
Industries Served
ArisGlobal was acquired by Nordic Capital on June 17, 2019, for $700 million. Additional investors include Athyrium Capital Management and Abbhi Capital. Total funding is reported as $2.36 million in earlier rounds.
Revenue is reported inconsistently across sources: $332.5 million projected for 2025, versus $23 million in older data.
Employee count is reported as 1,001-5,000, reflecting source figures of 1,113 (March 2024) and 2,003 elsewhere.
Browse all software products offered by ArisGlobal.
Multi-tenant SaaS Regulatory Information Management application from ArisGlobal, targeted at global pharma, biotech, medical device, and CRO regulatory affairs teams. Interoperates with LifeSphere Safety and includes an embedded GenAI/agentic AI layer (NavaX).
Multi-tenant SaaS pharmacovigilance and drug safety platform built on a cloud-native re-architecture of the legacy ARISg database, with end-to-end ICSR intake, MedDRA coding, E2B(R3) submission, aggregate reporting, and signal detection, plus an embedded GenAI/agentic AI layer (NavaX).
ArisGlobal's LifeSphere platform spans three product areas. LifeSphere RIM (Regulatory Information Management) covers product registrations, submission processes, and agency interactions, with IDMP-ready capabilities; a RIM solution for investigational-stage companies launched recently. Drug safety and pharmacovigilance capabilities cover adverse event management and safety surveillance throughout the product lifecycle. NavaX AI adds artificial intelligence capabilities across the platform, and the latest version integrates GenAI technology.
Multi-tenant SaaS architecture keeps all clients on the latest version through automatic updates. The platform is designed to meet FDA 21 CFR Part 11, EU GMP Annex 11, and other global computer system validation expectations.
Partnership information is undisclosed. ArisGlobal operates a multi-tenant SaaS platform with cloud-based infrastructure, and integrates with document, submission, labelling, and regulatory intelligence systems.
Support and services details are undisclosed. The multi-tenant SaaS delivery model is cloud-based. The platform is designed to meet global computer system validation expectations.
ArisGlobal leadership includes CEO Aman Wasan and CFO & President Glenn Renzulli. The company was founded in 1987, with 38 years of pharmaceutical software experience.
Nordic Capital acquired the company for $700 million in 2019. Named customers include AstraZeneca, Teva, Roche, and a global sixth-largest pharmaceutical company.
The platform is designed to meet FDA 21 CFR Part 11, EU GMP Annex 11, and other global computer system validation expectations. LifeSphere RIM offers IDMP-ready capabilities in regulatory information management.
Recent product launches include a RIM solution for investigational-stage companies. Nordic Capital's $700 million acquisition in 2019 and a projected $332.5 million revenue for 2025 are both on record, against an older $23 million revenue figure reported elsewhere.
ArisGlobal serves AstraZeneca, Teva, and Roche among named pharmaceutical customers. Its multi-tenant SaaS platform ships automatic updates to all clients.
The latest version integrates GenAI technology.
Headquarters
Coral Gables, Florida, United States
Founded
1987 (39 years in business)
Company Size
1001-5000 employees
Type
Private
Owned by Nordic Capital
Annual Revenue
Not Disclosed (2026)